The Nrf2-ARE pathway, which is the primary regulator of cellular redox equilibrium, reportedly mediates resistance to chemotherapy, demethylation therapy, and target therapy in various tumours [30–33]. The gene discussed is NFE2L2; the disease is neoplasm.